Telavancin labels and packages

Revision as of 00:08, 10 January 2014 by Chetan Lokhande (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Telavancin
Vibativ® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]

Labels And Packages

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 250 MG/VIAL LABEL

NDC 0469-3525-30

1 Vial

Vibativ™

(telavancin hydrochloride)

Equivalent to 250 mg telavancin

Rx only

Astellas

[[File:|800px|thumb]]

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 250 MG/VIAL CARTON

NDC 0469-3525-30

1 Carton containing 1 Vial of 250 mg

Vibativ™

(telavancin hydrochloride)

Equivalent to 250 mg telavancin per vial

Rx only

Astellas

[[File:|800px|thumb]]

PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 750 MG/VIAL LABEL

NDC 0469-3575-50

1 Vial

Vibativ™

(telavancin hydrochloride)

Equivalent to 750 mg telavancin

Rx only

Astellas

[[File:|800px|thumb]]


PACKAGE LABEL – PRINCIPAL DISPLAY PANEL – 750 MG/VIAL CARTON

NDC 0469-3575-50

1 Carton containing 1 Vial of 750 mg

Vibativ™

(telavancin hydrochloride)

Equivalent to 750 mg telavancin per vial

Rx only

Astellas[1]


[[File:|800px|thumb]]


References

  1. "VIBATIV (TELAVANCIN HYDROCHLORIDE) INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION [ASTELLAS PHARMA US INC.]".

Adapted from the FDA Package Insert.